tcf-no-longer-accepting-cases

Invega and Gynecomastia

Individuals and especially children who use Invega (paliperidone) to control mental illnesses may be at risk of gynecomastia (breast enlargement). Invega can increase the amount of a certain hormone called prolactin in a patient’s blood — a condition called hyperprolactinemia.

Symptoms of elevated prolactin levels include gynecomastia in men, decreased sexual ability, and nipple discharge. The manufacturer of Invega recommends that patients with these symptoms should contact their doctor right away.

Invega Gynecomastia Symptoms

Invega is associated with the following gynecomastia symptoms:

  • Enlargement of the male breasts: The enlargement is in glandular tissue, which produces a conical shape behind the nipple. It may affect one breast or both. It is usually symmetrical in appearance.
  • Breast tenderness and sensitivity: The breasts may be painful, but the pain is not typically extreme.
  • Nipple is swollen
  • Nipple is rubbery or firm: This is because gynecomastia involves glandular tissue, and not fatty deposits.
  • Nipple discharge
  • Psychological trauma: Gynecomastia can be very embarrassing and debilitating for an adolescent male.

Gynecomastia symptoms are very similar to symptoms of breast cancer, abscesses, or other serious medical conditions. Individuals who are concerned should seek medical attention.

 

Meet Your Attorney

Collen A. Clark

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

“Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

To contact Collen, please fill out the contact form below:

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 879-3040.
  • This field is for validation purposes and should be left unchanged.